The Filing Desk

Aveanna Healthcare

AVAH · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

AVAH · Last close · November 13, 2026
$11.50
Value Aveanna Healthcare yourself

Aveanna Healthcare's revenue rose 20.2% to $2.4 billion in fiscal 2025. Its operating margin was 10.5%, up from 6.9% a year earlier. The diluted share count rose 11.4%.

Aveanna Healthcare Holdings Inc. Latest fiscal year ended January 3, 2026 10-K filed March 19, 2026 · 0001193125-26-115851 Updated
Revenue
$2.4B
20.2%
Operating margin
10.5%
3.6 pts
Net income
$225M
 
Free cash flow
—
 
Return on capital
21.6%
15.2 pts
Market cap
$2.6B
Nov 13 close
P/E
8.2x
On $1.40 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Aveanna Healthcare does

Aveanna provides care in patients' homes for people with complex medical needs, from newborns and children to adults and seniors. Most care is given by nurses. Its patients are paid for mostly by government programs such as Medicaid and Medicare, and by private insurers.

It reports three segments. Private Duty Services is mostly private duty nursing, which means long hours of skilled nursing at home for medically complex children and young adults, plus pediatric therapy. Aveanna says it is the largest provider of this nursing in the United States. About 30% of these nursing patients are over 18. Home Health & Hospice serves mainly older people: home health care after surgery or illness, and end-of-life hospice care. Medical Solutions supplies tube-feeding formulas, equipment and respiratory supplies.

Aveanna sends bills to government programs and insurers for the care and supplies it provides. Hospitals, especially children's hospitals, send it many of its new patients. It says it competes with other home health, hospice and medical equipment companies. It grows by acquiring other home care businesses. In March 2026 it agreed to buy Family First, a pediatric home care provider with 27 locations in seven states.

Its biggest risks, as it describes them

  • Competition among home health, hospice and medical equipment companies.
  • Losing relationships with the hospitals and other sources that refer patients.
  • Cuts or limits in government and private insurance funding, or changes to Medicare rates and rules.
  • Being unable to control costs when it cannot set the rates it is paid, and shortages of nurses and other staff.
  • Heavy regulation, and delays in collecting payments for its services.
From Aveanna Healthcare's annual report on Form 10-K, filed March 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments30194484193
Debt incl. finance leases1,2361,2901,2861,2811,300
Net debt (negative means net cash)1,2061,2711,2421,1971,107
Net debt to EBITDA——56.8x8.0x4.1x
Debt to equity1.9x———6.7x
Interest coverage−0.5x−6.0x0.1x0.9x1.8x
Current ratio0.8x0.8x0.9x1.0x1.3x
Quick ratio0.8x0.8x0.9x1.0x1.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Aveanna Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Aveanna Healthcare says to expect

  • Full year 2026: revenueIncreased Full Year 2026 Revenue guidance to greater than $2.695 billion, updated from greater than $2.68 billion
  • Full year 2026: adjusted EBITDAIncreased Full Year 2026 Adjusted EBITDA guidance to greater than $374 million, updated from greater than $365 million
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Aveanna Healthcare reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 95 of 97 of 9
Rule of 40———
Altman Z''−2.98−2.25−0.46
Accruals ratio−9.5%−2.7%5.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsFailFailPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rosePassFailPass
Revenue rose relative to assetsPassPassPass
F-score6 of 95 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Aveanna Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Aveanna HealthcareFY2520.2%10.5%—21.6%4.1x7
Hims & Hers HealthFY2559.0%4.5%2.5%19.0%2.5x4Compare
ChemedFY254.1%13.4%12.9%27.3%−0.2x5Compare
Teladoc HealthFY25−1.5%−10.4%11.3%−12.5%2.1x6Compare
NateraFY2535.9%−13.4%4.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,3841,4951,6791,7881,8952,0242,433
Revenue growth—8.0%12.3%6.5%6.0%6.8%20.2%
Gross profit419454542553595636810
Research and development———————
Operating income39−4−36−6428140256
Net income−76−57−117−662−134−11225
Diluted EPS (US$)−0.56−0.40−0.69−3.57−0.71−0.061.05
Diluted shares (millions)137141171186190193215
Cash flow
Cash from operations−9117−11−482333126
Capital expenditure171516————
Free cash flow−25101−27————
Dividends paid0000000
Share buybacks0000000
Acquisitions117866720015
Stock-based compensation231416131825
Balance sheet at fiscal year end
Cash and short-term investments—13730194484193
Debt incl. finance leases—1,1761,2361,2901,2861,2811,300
Total assets—1,8442,3341,7121,6131,6632,012
Total liabilities—1,5771,6961,7161,7401,7861,817
Shareholders' equity270265636−6−130−124194
Margins and ratios
Gross margin30.3%30.4%32.3%30.9%31.4%31.4%33.3%
Operating margin2.8%−0.2%−2.1%−35.9%0.4%6.9%10.5%
Net margin−5.5%−3.8%−7.0%−37.0%−7.1%−0.5%9.2%
Free cash flow margin−1.8%6.8%−1.6%————
Rule of 40 (growth + FCF margin)—14.8%10.7%————
Return on capital——−1.8%−32.7%0.5%6.4%21.6%
Return on equity——−26.0%−210.3%———
Return on assets——−5.6%−32.7%−8.1%−0.7%12.2%
Net debt to EBITDA—76.7x——56.8x8.0x4.1x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Aveanna Healthcare's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Aveanna Healthcare.